Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain

- Patient has given written informed consent to participate in the study in accordance with local regulations

- Adult male and female patients ≥18 years of age at the time of screening

- Body mass index ≥18.0 to ≤40.0 kg/m2 at Screening

- Diagnosis of DPNP at Screening

- Pain from DPN present for at least 6 months

- A1C ≤11% at screening

- Stable regimen for the treatment of T1DM or T2DM for ≥1 month prior to Screening

- Presence of other painful conditions that may confound assessment or self-evaluation of DPNP

- History of major depressive episode, active, significant psychiatric disorders

- History of clinically significant drug or alcohol use disorder

- History of neurolytic or neurosurgical therapy for DPNP

- Use of opioid medications for management of DPNP within the 2 months prior to Screening Visit

- Use of NSAIDs less than 2 weeks prior to the Screening Visit